2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 2542

La Positive, Ro60 Negative Subset of Primary Sjögren’s Syndrome Is a Reality
Abstract Number: 985

Labial Salivary Gland Antibody-Secreting Cell Specificity and Characteristics in Sjögren’s Patients
Abstract Number: 739

Lack of Association Between Esophageal Symptoms and Abnormal Findings in High-Resolution Manometry in a Mexican Mestizo Cohort with Systemic Sclerosis (SSc)
Abstract Number: 1637

LACK of Association of ANTI CCP and Arthritis in SLE
Abstract Number: 1219

Lack of Gene-Diuretic Interactions on Risk of Incident Gout: The Nurses’ Health Study and Health Professionals Follow-up Study
Abstract Number: 639

Lack of Response Gene to Complement-32 Impairs Th17 Differentiation and Attenuates Lupus-like Chronic Graft Versus Host Disease
Abstract Number: 1700

Laser Speckle Contrast Analysis in the Follow-up of Digital Ulcers in Systemic Sclerosis Patients
Abstract Number: 477

Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials
Abstract Number: 1696

Left Atrial Area Measurement Is Useful for Evaluating Left Ventricular Diastolic Dysfunction Coexisting with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis
Abstract Number: 200

Leg Length Inequality and Hip Osteoarthritis
Abstract Number: 1025

Leptin Production By Osteoarthritis Synovial Fibroblasts: Stimulation By Glucocorticoids and Mineralocorticoids through the Glucocorticoid Receptor and GILZ (Glucocorticoid-Induced Leucine Zipper) Protein
Abstract Number: L10

Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Two Phase III Clinical Trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)
Abstract Number: 420

Less Is More: The Shorter Physical Function Measure Promis-PF10a Outperforms HAQ in an Ethnically Diverse, Urban Rheumatoid Arthritis Clinic Population
Abstract Number: 2363

Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis
Abstract Number: 1058

Levels of Fatigue Are Dependent on Country of Residence in Rheumatoid Arthritis: An Analysis Among 3920 Patients from 17 Countries
Abstract Number: 387

Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA
Abstract Number: 1346

Leveraging Electronic Health Records to Improve Vaccination Rates for Patients with Rheumatoid Arthritis
Abstract Number: 2351

Ligand of Glucocorticoid-Induced Tumor Necrosis Factor Receptor Enhances Th17 Cells Response in Collagen-Induced Arthritis Via P38 MAPK and STAT3 Pathway
Abstract Number: 2137

Linear Extrapolation of Missing Radiographic Progression Scores Does Not Spuriously overestimate overall Radiographic Progression in Rheumatoid Arthritis
Abstract Number: 399

Lipid Concentrations and Particle Sizes in Drug Naive Patients with Rheumatoid Arthritis
Abstract Number: 841

Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients
Abstract Number: 636

Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE
Abstract Number: 92

Long Noncoding RNA Nron Regulates the Activity of NFAT5 through Ubiquitin-Independent Proteasome Pathway in Rheumatoid Arthritis
Abstract Number: 293

Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Abstract Number: 1559

Long Term Improvements in Physical Function Are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients
Abstract Number: 1245

Long Term Outcome of Infliximab in Severe and Refractory Systemic Sarcoidosis: Report of 16 Cases
Abstract Number: 913

Long Term Outcomes of Patients with Moderate Creatine Kinase (CK) Elevation Seen in a Rheumatology Clinic
Abstract Number: 174

Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
Abstract Number: 479

Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years
Abstract Number: L22

Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Abstract Number: 1564

Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension
Abstract Number: 2517

Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Abstract Number: 2645

Long-Term Efficacy and Safety of Pulse Cyclophosphamide for Neuropsychiatric Systemic Lupus Erythematosus: A Two-Centre Experience
Abstract Number: 1674

Long-Term Efficacy of Rituximab in Systemic Sclerosis
Abstract Number: 957

Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity?
Abstract Number: 1782

Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors
Abstract Number: 298

Long-Term Impact of Juvenile Idiopathic Arthritis in the Greek adults’ Psychosocial Life
Abstract Number: 49

Long-Term Oral Bisphosphonate Use for Osteoporosis Among Older Women – US and Canadian Perspective
Abstract Number: 2763

Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet’s Disease
Abstract Number: 1781

Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years
Abstract Number: 813

Long-Term Outcomes of Takayasu’s Arteritis Patients with Renal Artery Involvement
Abstract Number: 294

Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 1159

Long-Term Quality of Life, Productivity Impairment, Disease Severity and Health Care Costs in Relation to Functional Impairment in Ankylosing Spondylitis Patients in the Czech Republic
Abstract Number: 273

Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis
Abstract Number: 545

Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Abstract Number: 2505

Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status
Abstract Number: 262

Longitudinal Assessment of Promis Pediatric Item Banks in Children with Chronic Musculoskeletal Pain
Abstract Number: 2931

Longitudinal Examination with Salivary Gland Ultrasonography (SGUS) of Patients with Primary Sjogren’s Syndrome: A Single Center Experience
Abstract Number: 1724

Loss of IRF5 Ameliorates Tissue Fibrosis in a Murine Model of Systemic Sclerosis
Abstract Number: 2907

Loss of microRNA-146a Exacerbates Inflammatory Arthritis
Abstract Number: 2561

Low Cardio-Respiratory Fitness Is Associated with Increased Arterial Stiffness in Patients with Ankylosing Spondylitis
Abstract Number: 1206

Low Dose Colchicine Anti-Inflammatory Effects Are Transduced By AMP-Activated Protein Kinase (AMPK)
Abstract Number: 1407

Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Abstract Number: 1427

Low Prevalence of Sarcopenic Obesity in Rheumatoid Arthritis Patients with Moderate Clinical Activity
Abstract Number: L3

Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Abstract Number: 111

Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy
Abstract Number: 1410

Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies?
Abstract Number: 2619

Low Socioeconomic Status (SES) As Measured By Education Is (not) Associated with Worse Outcome in SLE: Data from the 1000 Canadian Faces of Lupus
Abstract Number: 1394

Low Vitamin D Level Is Not Associated with Increased Risk of Cardiovascular Disease in Rheumatoid Arthritis Patients
Abstract Number: 220

Lower Extremity Presarcopenia Is Associated with the Severity of Knee Pain
Abstract Number: 235

Lower P1NP Serum Levels: a Predictive Marker of Bone Loss after One-Year Follow-up in premenopausal SLE Patients
Abstract Number: 2118

Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population-Based Cohort Study
Abstract Number: 734

Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Abstract Number: 878

Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment
Abstract Number: 2791

Lung Cancer in SLE
Abstract Number: 2976

Lung Ultrasound Screening for Interstitial Lung Disease in Rheumatoid Arthritis. Comparison with Usual Detection Algorithms in Clinical Practice
Abstract Number: 705

Lupus Chest Pain in the Emergency Department: a Common Diagnostic Dilemma
Abstract Number: 2989

Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus
Abstract Number: 694

Lupus Myocarditis: Clinical, Echocardiographic and Magnetic Resonance Characteristics
Abstract Number: 1311

Lupus Nephritis in Mexican Children
Abstract Number: 1662

Lupus Nephritis Patients Who Stopped Maintenance Immunosuppressive Therapy without Relapse
Abstract Number: 1655

Lupus Nephritis: Clinicopathological Correlation in 126 Biopsies
Abstract Number: 690

Lupus Patients Requiring First Corticosteroid Intervention Late in Disease Course – a Phenotypic Description
Abstract Number: 713

Lupuspro Is Responsive to Changes in Disease Activity over Time
Abstract Number: 1

Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].